公开(公告)号：WO2021216567A1

公开(公告)日：2021-10-28

申请号：PCT/US2021/028181

申请日：2021-04-20

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES INC.

Inventor： REITER, Mark S. ,  MILLSAPS, Clara R. ,  MASON, John ,  WHITEHURST, Brooks

IPC: C05F3/00 ,  C05G1/00 ,  C05G5/12

Abstract: Described herein is a process that converts an ash source such as, for example, a manure ash source to granules with increased nutrient solubility and phosphorus (P) content. In one aspect, the process involves admixing an ash source with a phosphorous-based acid to produce the granules. The granulated composition produced by the methods described herein have good packing properties and, thus, are easy to transport and apply as a fertilizer. The granular compositions produced herein can be readily used in conventional fertilizer equipment, mixes, and systems.

公开(公告)号：WO2021178496A1

公开(公告)日：2021-09-10

申请号：PCT/US2021/020606

申请日：2021-03-03

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES INC.

Inventor： KONG, Ping

IPC: A01N63/20

Abstract: The disclosure, in one aspect, relates to compositions containing non-pathogenic Burkholderia species SSG and/or extracts from SSG cultures and methods of making and using the same. Also disclosed are methods for treating and preventing plant diseases caused by pathogens, the methods including applying the disclosed compositions to plants and/or soil, diseased leaf debris, or other plant growth media surrounding the plants. Finally, disclosed are methods for increasing plant growth using the disclosed compositions. The compositions are effective as well as environmentally benign and are not detrimental to human or animal health This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

公开(公告)号：WO2021016524A1

公开(公告)日：2021-01-28

申请号：PCT/US2020/043418

申请日：2020-07-24

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES INC.

Inventor： FENG, Ziang ,  YANG, Shuo ,  WANG, Anbo ,  JIA, Xiaoting ,  ZUO, Lei ,  YU, Li

IPC: A41D1/00 ,  A41D31/00 ,  H02N1/04

Abstract: Aspects of triboelectric fibers and methods of manufacture of the fibers are described. In one example, a method of manufacture of a fiber for generating energy using the triboelectric effect includes forming a preform tube, heating the preform tube in a furnace, feeding a wire through the preform tube and the furnace during the heating, and pulling the wire through the furnace to form a fiber. The methods described herein can be relied upon to manufacture fibers long enough for industrial-scale textile manufacturing, including for use with industrial-scale looms. In one example, forming the preform tube can include providing a polypropylene tube and wrapping the polypropylene tube with a housing layer of amorphous film, such as acrylic film. The acrylic film can be relied upon to maintain the form and integrity of the polypropylene as the wire is pulled, and the acrylic film can be easily removed after the pulling.

公开(公告)号：WO2020096711A1

公开(公告)日：2020-05-14

申请号：PCT/US2019/053708

申请日：2019-09-28

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

Inventor： THOLL, Dorothea ,  LANCASTER, Jason

IPC: C12Q1/68 ,  C12N15/09 ,  C12N9/10

Abstract: Described herein are engineered polynucleotides and vectors capable of encoding one or more engineered southern green stink bug pheromone synthesis enzymes. Also described herein are engineered southern green stink bug pheromone synthesis enzymes. Also described herein are methods of making modified plants capable of expressing one or more southern green stink bug pheromone synthesis enzymes.

公开(公告)号：WO2020061254A1

公开(公告)日：2020-03-26

申请号：PCT/US2019/051830

申请日：2019-09-19

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

Inventor： KELLY, Deborah F. ,  LIANG, Yanping ,  DEARNALEY, William

IPC: C07K14/435 ,  C07K14/47 ,  C12N9/48

Abstract: Described herein are BRCA1 modulating compounds and formulations thereof. In some aspects, the BRCA1 modulating compound is a deubiquitinase. In some aspects, the BRCA1 modulating compound is a deubiquitinase inhibitor. as Also described herein are methods of treating a subject in need thereof with a BRCA1 modulating compound or formulation thereof. In some aspects, the subject in need thereof can have a cancer. In some aspects, the subject in need thereof has one or more BRCA1 mutations.

公开(公告)号：WO2020028439A1

公开(公告)日：2020-02-06

申请号：PCT/US2019/044248

申请日：2019-07-30

Applicant: VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY ,  VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. ,  GOURDIE, Robert G.

Inventor： GOURDIE, Robert G. ,  JOURDAN, L. Jane ,  ROGERS, Eda

IPC: A61K38/17 ,  C07K14/47 ,  C07K14/705

Abstract: Described herein are engineered hemichannels, engineered vesicles that can contain the one or more of the engineered hemichannels, pharmaceutical formulations thereof, and uses thereof. In some aspects, the engineered vesicles can include one or more cargo molecules. Also described herein are methods of loading the engineered vesicles. In some aspects, loading of one or more cargo molecules engineered vesicles can be optionally via an engineered hemichannel contained in the engineered vesicle.

公开(公告)号：WO2019204813A1

公开(公告)日：2019-10-24

申请号：PCT/US2019/028544

申请日：2019-04-22

Applicant: VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

Inventor： SANTOS, Webster L. ,  SALAMOUN, Joseph Michael ,  GARCIA, Christopher J. ,  MURRAY, Jacob H.

IPC: C07D498/04 ,  A61P3/04 ,  A61P3/00 ,  A61P25/16 ,  A61P25/28 ,  A61P35/00 ,  A61P37/00 ,  A61P3/10 ,  A61K31/4985 ,  A61K31/437

Abstract: The disclosure provide compounds of Formula I and the pharmaceutically acceptable salts thereof. The variables, R 1 , R 2 , R 3 , X 1 , X 2 , and Z are defined herein. Certain compounds of Formula I act as selective mitochondrial protonophore uncouplers that do not affect the plasma membrane potential. Compounds and salts of Formula I are useful for treating or decreasing the risk of conditions responsive to mitochondrial uncoupling, such as cancer, obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Because mitochondrial uncouplers decrease the production of reactive oxygen species (ROS), which are known to contribute to age-related cell damage, compounds of Formula I are useful for increasing lifespan. Compounds and salts of Formula I are also useful for regulating glucose homeostasis or insulin action in a patient.

公开(公告)号：WO2019157407A1

公开(公告)日：2019-08-15

申请号：PCT/US2019/017396

申请日：2019-02-09

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. ,  RIFFLE, Judy S. ,  LANE, Ozma R. ,  DARYAEI, Amin ,  ROY-CHOUDHURY, Shreya ,  FREEMAN, Benny D. ,  JANG, Eui Soung ,  NARANG, Gurtej S. ,  LESKO, John J. ,  SCHUMACHER, Trevor

Inventor： RIFFLE, Judy S. ,  LANE, Ozma R. ,  DARYAEI, Amin ,  ROY-CHOUDHURY, Shreya ,  FREEMAN, Benny D. ,  JANG, Eui Soung ,  NARANG, Gurtej S. ,  LESKO, John J. ,  SCHUMACHER, Trevor

IPC: B01D71/68 ,  B01D71/52 ,  C02F103/08 ,  C08G75/23

Abstract: Described herein are water desalination membranes and methods of desalinating water. Sulfonated poly(arylene ether) polymers are also disclosed, including those comprising one or more sulfonate groups at various points along the polymer chain. The polymers may be used as at least a portion of a water desalination membrane. The polymers described herein are useful for preventing transport of aqueous ionic species (e.g., Na+ and Cl-) across a membrane made from the polymers while allowing water to pass. Chlorine-stable polymers are described, as well as polymers exhibiting good performance for rejecting monovalent cations in the presence of polyvalent cations.

公开(公告)号：WO2019157377A1

公开(公告)日：2019-08-15

申请号：PCT/US2019/017349

申请日：2019-02-08

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. ,  RIFFLE, Judy, S. ,  LANE, Ozma, R. ,  DARYAEI, Amin ,  ROY-CHOUDHURY, Shreya ,  FREEMAN, Benny ,  JANG, Eui, Soung ,  NARANG, Gurtej, S. ,  LESKO, John, J. ,  SCHUMACHER, Trevor

Inventor： RIFFLE, Judy, S. ,  LANE, Ozma, R. ,  DARYAEI, Amin ,  ROY-CHOUDHURY, Shreya ,  FREEMAN, Benny ,  JANG, Eui, Soung ,  NARANG, Gurtej, S. ,  LESKO, John, J. ,  SCHUMACHER, Trevor

IPC: B01J39/20 ,  C08G65/48 ,  C09D171/12

Abstract: Described herein are water desalination membranes and methods of desalinating water. Sulfonated poly(arylene ether) polymers are also disclosed, including those comprising one or more sulfonate groups at various points along the polymer chain. The polymers may be used as at least a portion of a water desalination membrane. The polymers described herein are useful for preventing transport of aqueous ionic species (e.g., Na + and Cl - ) across a membrane made from the polymers while allowing water to pass. Chlorine-stable polymers are described, as well as polymers exhibiting good performance for rejecting monovalent cations in the presence of polyvalent cations.

公开(公告)号：WO2018217757A1

公开(公告)日：2018-11-29

申请号：PCT/US2018/033901

申请日：2018-05-22

Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION ,  VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.

Inventor： HOEHN, Kyle ,  SANTOS, Webster L. ,  CHILDRESS, Elizabeth S. ,  DAI, Yumin ,  MURRAY, Jacob ,  SANTIAGO-RIVERA, Jose

IPC: A61K31/4965 ,  A61K31/4985 ,  A61P3/08 ,  A61P3/10

Abstract: This disclosure provides compounds of Formula I, II, and III and pharmaceutically acceptable salts thereof for use as mitochondrial uncouplers, where the variables, e.g. R 1 -R 9 , (I) (II) (III) X 1 , X 2 , and Y 1 are defined in the specification. The disclosure also provides pharmaceutical compositions comprising a compound or pharmaceutically acceptable salt of Formula I, II, or III, alone or in combination with another active compound. Compounds and compositions of Formula I, II, and III are useful for treating or preventing certain conditions responsive to mitochondrial uncoupling such as obesity, type II diabetes, fatty liver disease, insulin resistance, Parkinson's disease, ischemia reperfusion injury, heart failure, non-alcoholic fatty liver disease (NALFD), and non-alcoholic steatohepatitis (NASH). Compounds of Formula I, II, and III are also useful for regulating glucose homeostatis and insulin action.